High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation.
High-quality and robust protein quantification in large clinical/pharmaceutical cohorts with IonStar proteomics investigation.
复制标题
DOI：
10.1038/s41596-022-00780-w
复制
发表时间：
2023-03
期刊：
影响因子：
14.8
通讯作者：
Qu, Jun
中科院分区：
文献类型：
--
作者：
Shen, Shichen;Wang, Xue;Zhu, Xiaoyu;Rasam, Sailee;Ma, Min;Huo, Shihan;Qian, Shuo;Zhang, Ming;Qu, Miao;Hu, Chenqi;Jin, Liang;Tian, Yu;Sethi, Sanjay;Poulsen, David;Wang, Jianmin;Tu, Chengjian;Qu, Jun
Robust, reliable quantification of large sample cohorts is often essential for meaningful clinical or pharmaceutical proteomics investigations, but it is technically challenging. When analyzing very large numbers of samples, isotope labeling approaches may suffer from substantial batch effects, and even with label-free methods, it becomes evident that low-abundance proteins are not reliably measured owing to unsufficient reproducibility for quantification. The MS1-based quantitative proteomics pipeline IonStar was designed to address these challenges. IonStar is a label-free approach that takes advantage of the high sensitivity/selectivity attainable by ultrahigh-resolution (UHR)-MS1 acquisition (e.g., 120–240k full width at half maximum at m/z = 200) which is now widely available on ultrahigh-field Orbitrap instruments. By selectively and accurately procuring quantitative features of peptides within precisely defined, very narrow m/z windows corresponding to the UHR-MS1 resolution, the method minimizes co-eluted interferences and substantially enhances signal-to-noise ratio of low-abundance species by decreasing noise level. This feature results in high sensitivity, selectivity, accuracy and precision for quantification of low-abundance proteins, as well as fewer missing data and fewer false positives. This protocol also emphasizes the importance of well-controlled, robust experimental procedures to achieve high-quality quantification across a large cohort. It includes a surfactant cocktail-aided sample preparation procedure that achieves high/reproducible protein/peptide recoveries among many samples, and a trapping nano-liquid chromatography–mass spectrometry strategy for sensitive and reproducible acquisition of UHR-MS1 peptide signal robustly across a large cohort. Data processing and quality evaluation are illustrated using an example dataset (http://proteomecentral.proteomexchange.org), and example results from pharmaceutical project and one clinical project (patients with acute respiratory distress syndrome) are shown. The complete IonStar pipeline takes ~1–2 weeks for a sample cohort containing ~50–100 samples.
登录
查看更多内容
影响因子：
4.4
作者：
Tu, Chengjian;Beharry, Kay D.;Shen, Xiaomeng;Li, Jun;Wang, Lianshui;Aranda, Jacob V.;Qu, Jun
通讯作者：
Qu, Jun
蛋白质组分析前样品制备的蛋白质沉淀方法的比较。
影响因子：
4.1
作者：
Jiang, L;He, L;Fountoulakis, M
通讯作者：
Fountoulakis, M
影响因子：
9.6
作者：
Dahmer, Mary K.;Flori, Heidi;Quasney, Michael W.
通讯作者：
Quasney, Michael W.
影响因子：
3.4
作者：
Levin, Yishai
通讯作者：
Levin, Yishai
影响因子：
5.6
作者：
Shen S;Zhang M;Ma M;Rasam S;Poulsen D;Qu J
通讯作者：
Qu J